MUC5B and prostate carcinoma: Comparing the mutations in pre- and post- resistant samples, we also fund that MUC7 and MUC5B mutation repair may be associated with longer PFS and ZNF91 mutation may be a key factor contributing to the development of drug resistance in prostate cancer.